Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib with Chemoradiation and Chemotherapy in Resected Pancreatic Cancer
NCT00313560Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2006
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Mar 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00313560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313560.